<DOC>
	<DOC>NCT00570063</DOC>
	<brief_summary>To assess the efficacy and safety of an investigational compound PF-02545920 for the treatment of schizophrenia. PF-02545920 will be more effective than placebo in reducing symptoms associated with schizophrenia.</brief_summary>
	<brief_title>Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety &amp; Efficacy Of PF-02545920 Compared With Placebo</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>1. Have a current diagnosis of schizophrenia. 2. Increase in symptoms over the past 24 weeks. 3. Willing to remain inpatients for the duration of the trial. 1. Evidence or history of clinically significant medical problems. 2. Females of childbearing potential. 3. A primary psychiatric diagnosis other than schizophrenia. 4. A diagnosis of substance abuse or dependence in the last 6 months.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Schizophrenia, acute exacerbation, and PF-02545920</keyword>
</DOC>